Terazosin: Difference between revisions
Brian Blank (talk | contribs) No edit summary |
Brian Blank (talk | contribs) No edit summary |
||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
<small>'''''Synonyms / Brand Names:''''' Terazosin HCl, Terazosin hydrochloride, Terazosina, Terazosine, Terazosinum, Trazosin HCl, Abbott 45975, Blavin, Flumarc, Fosfomic, Heitrin, Hytracin, Hytrin, Hytrinex, Itrin, Urodie, Vasocard, Vasomet, Vicard</small> | <small>'''''Synonyms / Brand Names:''''' Terazosin HCl, Terazosin hydrochloride, Terazosina, Terazosine, Terazosinum, Trazosin HCl, Abbott 45975, Blavin, Flumarc, Fosfomic, Heitrin, Hytracin, Hytrin, Hytrinex, Itrin, Urodie, Vasocard, Vasomet, Vicard</small> | ||
| Line 14: | Line 13: | ||
'''Hypertension''' | '''Hypertension''' | ||
*Initial dose: 1 mg at bedtime is the starting dose for all patients, and this dose should not be exceeded. This initial dosing regimen should be strictly observed to minimize the potential for severe hypotensive effects. | *Initial dose: 1 mg at bedtime is the starting dose for all patients, and this dose should not be exceeded. This initial dosing regimen should be strictly observed to minimize the potential for severe hypotensive effects. | ||
{{FDA}} | {{FDA}} | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
{{SIB}} | |||
{{WH}} | |||
{{WS}} | |||
Revision as of 14:46, 19 May 2009
|
WikiDoc Resources for Terazosin |
|
Articles |
|---|
|
Most recent articles on Terazosin |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Terazosin at Clinical Trials.gov Clinical Trials on Terazosin at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Terazosin
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Terazosin Discussion groups on Terazosin Directions to Hospitals Treating Terazosin Risk calculators and risk factors for Terazosin
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Terazosin |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Synonyms / Brand Names: Terazosin HCl, Terazosin hydrochloride, Terazosina, Terazosine, Terazosinum, Trazosin HCl, Abbott 45975, Blavin, Flumarc, Fosfomic, Heitrin, Hytracin, Hytrin, Hytrinex, Itrin, Urodie, Vasocard, Vasomet, Vicard
Dosing and Administration
Benign prostatic hyperplasia
- Initial dose: 1 mg at bedtime is the starting dose for all patients, and this dose should not be exceeded as an initial dose. Patients should be closely followed during initial administration in order to minimize the risk of severe hypotensive response.
Hypertension
- Initial dose: 1 mg at bedtime is the starting dose for all patients, and this dose should not be exceeded. This initial dosing regimen should be strictly observed to minimize the potential for severe hypotensive effects.
Adapted from the FDA Package Insert.
Template:SIB